FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204806602> ?p ?o ?g. }

• W3204806602 abstract "Abstract Malignant rhabdoid tumors (MRTs) are rare, aggressive pediatric solid tumors, characterized by a 22q11 deletion that inactivates the SMARCB1 gene. Outcomes remain poor despite multimodality treatment. MRTs are among the most genomically stable cancers and lack therapeutically targetable genetic mutations. We utilized metaVIPER, an extension of the Virtual Inference of Protein-activity by Enriched Regulon (VIPER) algorithm, to computationally infer activated druggable proteins in the tumor of an eight month old patient and then expanded the analysis to TCGA and TARGET cohorts. In vitro studies were performed on a panel of MRT and atypical teratoid/rhabdoid tumor cell lines. Two patient-derived xenograft (PDX) mouse models of MRT were used for in vivo efficacy studies. MetaVIPER analysis from the patient’s tumor identified significantly high inferred activity of nuclear export protein Exportin-1 (XPO1). Expanded metaVIPER analysis of TCGA and TARGET cohorts revealed consistent elevations in XPO1 inferred activity in MRTs compared to other cancer types. All MRT cell lines demonstrated baseline activation of XPO1. MRT cell lines demonstrated in vitro sensitivity to the XPO1 inhibitor, selinexor which led to cell cycle arrest and induction of apoptosis. Targeted inhibition of XPO1 in patient-derived xenograft models of MRT using selinexor resulted in abrogation of tumor growth. Selinexor demonstrates efficacy in preclinical models of MRT. These results support investigation of selinexor in a phase II study in children with MRT and illustrate the importance of an N-of-1 approach in driving discovery beyond the single patient. Statement of Translational Relevance We describe the patient-driven discovery of XPO1 activation as a non-genetically encoded vulnerability in MRTs. The application of metaVIPER analysis to tumors lacking actionable oncogenic alterations represents a novel approach for identifying potential therapeutic targets and biomarkers of response. Our preclinical validation of selinexor confirms XPO1 inhibition as a promising therapeutic strategy for the treatment of MRT." @default.
• W3204806602 created "2021-10-11" @default.
• W3204806602 creator A5024631207 @default.
• W3204806602 creator A5027075602 @default.
• W3204806602 creator A5028453851 @default.
• W3204806602 creator A5031841410 @default.
• W3204806602 creator A5039574165 @default.
• W3204806602 creator A5041560164 @default.
• W3204806602 creator A5042826164 @default.
• W3204806602 creator A5046655874 @default.
• W3204806602 creator A5060387400 @default.
• W3204806602 creator A5061020283 @default.
• W3204806602 creator A5062320984 @default.
• W3204806602 creator A5068589183 @default.
• W3204806602 creator A5075359131 @default.
• W3204806602 date "2021-10-02" @default.
• W3204806602 modified "2023-10-09" @default.
• W3204806602 title "Identification and validation of a non-genetically encoded vulnerability to XPO1 inhibition in malignant rhabdoid tumors – expanding patient-driven discovery beyond the N-of-1" @default.
• W3204806602 cites W1535350845 @default.
• W3204806602 cites W1760824447 @default.
• W3204806602 cites W1976106807 @default.
• W3204806602 cites W1993740381 @default.
• W3204806602 cites W2009720434 @default.
• W3204806602 cites W2016077902 @default.
• W3204806602 cites W2036524556 @default.
• W3204806602 cites W2042962536 @default.
• W3204806602 cites W2056989888 @default.
• W3204806602 cites W2064423959 @default.
• W3204806602 cites W2071268727 @default.
• W3204806602 cites W2097495832 @default.
• W3204806602 cites W2102074241 @default.
• W3204806602 cites W2105280376 @default.
• W3204806602 cites W2106578635 @default.
• W3204806602 cites W2110265246 @default.
• W3204806602 cites W2123101814 @default.
• W3204806602 cites W2132310381 @default.
• W3204806602 cites W2136307922 @default.
• W3204806602 cites W2146475919 @default.
• W3204806602 cites W2166670794 @default.
• W3204806602 cites W2169456326 @default.
• W3204806602 cites W2179438025 @default.
• W3204806602 cites W223909586 @default.
• W3204806602 cites W2402362653 @default.
• W3204806602 cites W2462779032 @default.
• W3204806602 cites W2472255748 @default.
• W3204806602 cites W2495597122 @default.
• W3204806602 cites W2503294204 @default.
• W3204806602 cites W2520937393 @default.
• W3204806602 cites W2564365886 @default.
• W3204806602 cites W2566656214 @default.
• W3204806602 cites W2602169105 @default.
• W3204806602 cites W2605858714 @default.
• W3204806602 cites W2610540653 @default.
• W3204806602 cites W2764230521 @default.
• W3204806602 cites W2806006952 @default.
• W3204806602 cites W2808357284 @default.
• W3204806602 cites W2920841323 @default.
• W3204806602 cites W2950676576 @default.
• W3204806602 cites W2969931905 @default.
• W3204806602 cites W2996500406 @default.
• W3204806602 cites W3099289621 @default.
• W3204806602 cites W4241962913 @default.
• W3204806602 cites W4292157265 @default.
• W3204806602 doi "https://doi.org/10.1101/2021.10.02.462793" @default.
• W3204806602 hasPublicationYear "2021" @default.
• W3204806602 type Work @default.
• W3204806602 sameAs 3204806602 @default.
• W3204806602 citedByCount "1" @default.
• W3204806602 countsByYear W32048066022022 @default.
• W3204806602 crossrefType "posted-content" @default.
• W3204806602 hasAuthorship W3204806602A5024631207 @default.
• W3204806602 hasAuthorship W3204806602A5027075602 @default.
• W3204806602 hasAuthorship W3204806602A5028453851 @default.
• W3204806602 hasAuthorship W3204806602A5031841410 @default.
• W3204806602 hasAuthorship W3204806602A5039574165 @default.
• W3204806602 hasAuthorship W3204806602A5041560164 @default.
• W3204806602 hasAuthorship W3204806602A5042826164 @default.
• W3204806602 hasAuthorship W3204806602A5046655874 @default.
• W3204806602 hasAuthorship W3204806602A5060387400 @default.
• W3204806602 hasAuthorship W3204806602A5061020283 @default.
• W3204806602 hasAuthorship W3204806602A5062320984 @default.
• W3204806602 hasAuthorship W3204806602A5068589183 @default.
• W3204806602 hasAuthorship W3204806602A5075359131 @default.
• W3204806602 hasBestOaLocation W32048066021 @default.
• W3204806602 hasConcept C104317684 @default.
• W3204806602 hasConcept C105696609 @default.
• W3204806602 hasConcept C10679952 @default.
• W3204806602 hasConcept C121608353 @default.
• W3204806602 hasConcept C126322002 @default.
• W3204806602 hasConcept C143998085 @default.
• W3204806602 hasConcept C190283241 @default.
• W3204806602 hasConcept C207001950 @default.
• W3204806602 hasConcept C29537977 @default.
• W3204806602 hasConcept C2993561819 @default.
• W3204806602 hasConcept C502942594 @default.
• W3204806602 hasConcept C54355233 @default.
• W3204806602 hasConcept C60644358 @default.
• W3204806602 hasConcept C70721500 @default.
• W3204806602 hasConcept C71924100 @default.
• W3204806602 hasConcept C86803240 @default.

• next